Background. Postoperative pain is a major challenge for patients undergoing breast reconstruction after surgical treatment of breast cancer, resulting in prolonged hospitalizations and additional resource utilization. Evidence on the efficacy of techniques to minimize postoperative pain in autologous breast reconstruction is lacking. We sought to determine whether preoperative paravertebral block (PVB), a regional anesthetic technique, affects postoperative pain control and hospital length of stay (LOS) in patients undergoing autologous breast reconstruction. Methods. Consecutive patients undergoing postmastectomy autologous breast reconstruction between 2012 and 2015 were identified from a prospectively collected database to compare those who received PVB to those who did not. Primary outcomes included self-reported pain score, time to oral-only narcotic usage (TTON), and LOS. Sample differences were compared using Wilcoxon rank-sum and Chi square tests for continuous and categorical variables. Improvements in the comprehensive treatment of breast cancer and the implementation of the Women's Health and Cancer Rights Act in 1998 mandating universal coverage for postmastectomy breast reconstruction have led to steady increases in the national rates of reconstruction utilization after mastectomy. 2, 3 This trend corroborates evidence demonstrating women undergoing breast reconstruction after mastectomy have significantly improved health-related quality of life compared to women who do not undergo postmastectomy breast reconstruction, including greater satisfaction with appearance and higher physical, psychosocial, and sexual well-being. [4] [5] [6] [7] A major challenge for patients undergoing postmastectomy breast reconstruction is postoperative pain, which results in prolonged hospitalizations and additional resource utilization. In the last several years, strategies to alleviate postoperative pain in patients with breast cancer undergoing surgical treatment have been increasingly expounded in the literature. Particularly promising among these is the regional anesthesia technique of preoperative paravertebral block (PVB) administration in additional to general anesthesia, which has consistently been demonstrated to improve postoperative pain control and decrease
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Improvements in the comprehensive treatment of breast cancer and the implementation of the Women's Health and Cancer Rights Act in 1998 mandating universal coverage for postmastectomy breast reconstruction have led to steady increases in the national rates of reconstruction utilization after mastectomy. 2, 3 This trend corroborates evidence demonstrating women undergoing breast reconstruction after mastectomy have significantly improved health-related quality of life compared to women who do not undergo postmastectomy breast reconstruction, including greater satisfaction with appearance and higher physical, psychosocial, and sexual well-being. [4] [5] [6] [7] A major challenge for patients undergoing postmastectomy breast reconstruction is postoperative pain, which results in prolonged hospitalizations and additional resource utilization. In the last several years, strategies to alleviate postoperative pain in patients with breast cancer undergoing surgical treatment have been increasingly expounded in the literature. Particularly promising among these is the regional anesthesia technique of preoperative paravertebral block (PVB) administration in additional to general anesthesia, which has consistently been demonstrated to improve postoperative pain control and decrease length of stay (LOS) in patients with breast cancer undergoing mastectomy and/or prosthetic breast reconstruction. [8] [9] [10] [11] [12] However, to our knowledge, there are no studies that evaluate the potential benefit of a PVB in patients with breast cancer undergoing autologous microvascular breast reconstruction after mastectomy. Given that patients undergoing autologous reconstruction often require extended hospital stays and narcotic usage, we hypothesized that PVB administration can have substantial benefits for this patient population.
The purpose of this study was to determine if a preoperative PVB affects postoperative pain control and LOS in patients with breast cancer undergoing autologous microvascular breast reconstruction after mastectomy.
METHODS

Study Design and Patient Population
This is a cohort analysis comparing patients who received preoperative PVB in addition to general anesthesia versus patients who only received general anesthesia before undergoing autologous, abdominally based, microvascular breast reconstruction after mastectomy for breast cancer. Consecutive patients undergoing autologous reconstruction after mastectomy by a single surgeon at Siteman Cancer Center, Washington University School of Medicine, from June 2012 to June 2015 comprised the study population and were identified from a prospectively collected database with institutional review board approval (#201404004).
Autologous reconstruction was defined as a microvascular free flap transfer of the patient's abdominal tissue (autologous) to their breast and included muscle-sparing transverse rectus abdominis myocutaneous (ms-TRAM) flaps and deep inferior epigastric perforator (DIEP) flaps. Patients were ineligible for inclusion if they underwent prosthetic (tissue expander or implant based) breast reconstruction, a synchronous nonbreast procedure at time of reconstruction, non-abdominally based microvascular reconstruction (e.g., superior gluteal artery perforator flap), or pedicled, nonmicrovascular, autologous reconstruction (e.g., latissimus dorsi flap or pedicled TRAM flap).
Pertinent covariates were tabulated for each patient. Clinical variables included age, body mass index (BMI), preoperative opioid use, American Society of Anesthesiology (ASA) classification, history of postoperative nausea/ vomiting, and comorbidities. Pathologic variables included history of adjuvant therapy, mastectomy type, mastectomy location, cancer stage, and cancer laterality. Reconstructive variables included location (unilateral vs. bilateral), timing after mastectomy (immediate vs. delayed), and flap type.
PVB and Operative Procedure
The main exposure variable was PVB administration, with block failure (inadequate anesthetic response) and block complications (complications resulting from block administration) tabulated. All patients scheduled to have autologous reconstruction after mastectomy were offered a PVB by a dedicated regional anesthesia service directed by a fellowship-trained anesthesiologist. All blocks were performed in the preoperative area before surgery, with unilateral blocks placed for patients undergoing unilateral surgery and bilateral blocks placed for patients undergoing bilateral surgery. Appropriate ASA standards were followed with full cardiovascular monitoring and supplemental oxygen provided throughout administration. In all cases, time-out was performed, and sterile technique was used to administer the anesthetic using a 20-or 21-gauge needle under ultrasound guidance (Sonosite Snerve). Incremental injection technique was performed, which was composed of 15 mL of 0.5 % bupivacaine (per side, 30 mL total in bilateral cases), in the paravertebral space at the T2-4 levels. All patients had surgery under general anesthesia. No patients received an implantable local anesthetic device in the abdominal portion of the procedure. Intraoperative antiemetics were administered at the discretion of the anesthesia provider and included a combination of the following: scopolamine transdermal patch, intravenous metoclopramide, intravenous ondansetron, and intravenous dexamethasone. Postoperatively, patients were taken to the postanesthesia care unit (PACU) and subsequently admitted to a specialty care hospital floor.
Outcome Measures and Data Collection
The primary outcome variables of interest were: selfreported pain score at 2 h, self-reported pain score at 24 h, time to usage of oral-only narcotics (TTON), LOS in hours, and LOS in hospital nights. Nursing staff, unaware of the study hypothesis, recorded patients' self-reported pain scores at 2 and 24 h on a verbal numeric rating scale from 0 to 10, with 0 indicating no pain and 10 indicating the worst pain imaginable. TTON was calculated, in hours, as the time from PACU admission to the time of first oral narcotic use without concomitant intravenous narcotic use. LOS was counted from the end of the surgical procedure, defined as the time of PACU admission, to the time of hospital discharge and was measured in hours and hospital nights. The decision to discharge patients was made by the surgical team and reflected a consistent criteria based on patients tolerating a regular oral diet without discomfort, ambulating, having pain control with oral-only medications, and affirming their comfort with continuing care at home. Secondary outcomes of interest included postoperative nausea, defined as the need for an oral or intravenous antiemetic, and postoperative emesis. Any patient experiencing a thrombotic flap complication requiring operative takeback during initial hospital admission was excluded from this study. The rationale behind excluding these patients is a takeback would prolong LOS and potentially postoperative pain, which would therefore confound the relationship between the exposure variable and outcome variables. Each of these cases was reviewed to ensure that the reason for operative takeback was not related to PVB. Patients with unsuccessful blocks were not excluded from analysis.
Statistical Analysis
Established methods were used to characterize sample distributions, with Wilcoxon rank-sum analysis used to compare sample continuous variables and Chi square analysis used to compare sample categorical variables. Density distributions were used to estimate self-reported pain score at 2 h and at 24 h postoperatively, with Wilcoxon rank-sum analysis used to compare samples for this outcome. Kaplan-Meier analysis was used to estimate TTON, LOS in hours, and LOS in hospital nights. Use of oral-only narcotic pain medication was censored in calculating TTON, while hospital discharge was censored in calculating LOS in hours and LOS in hospital nights. Sample differences in these outcomes were tested by the Mantel-Cox log-rank test. Two-sided a = 0.05 was set a priori to detect significance, and all statistical analyses were conducted using commercially available software (SAS 9.4; SAS Institute, Cary, NC).
RESULTS
Patient Population
A total of 86 patients with breast cancer undergoing autologous, abdominally based microvascular breast reconstruction after mastectomy were consecutively enrolled onto this study. From this initial cohort, 8 patients (3 in the PVB group and 5 in the non-PVB group) experienced a postoperative complication requiring an immediate return to the operating room; therefore, these patients were excluded from analysis, leaving a total study population of 78 patients. Of these, 39 patients received a PVB and 39 patients did not. There were no significant differences in patient and treatment characteristics between the two groups, including age, BMI, ASA score, and medical comorbidities, as demonstrated in Table 1 .
Surgical Procedures
A total of 119 autologous reconstructions were performed after 123 mastectomy procedures in the 78 study patients (21 bilateral reconstructions in the PVB group vs. 20 bilateral reconstructions in the non-PVB group, p = 0.82) ( Table 1) . For patients receiving a PVB, autologous reconstruction was performed utilizing a unilateral DIEP flap in 16 (41 %) cases, a ms-TRAM flap in 2 (5 %), bilateral DIEP flaps in 11 (28 %), and bilateral ms-TRAM flaps in 10 (26 %). Flap utilization for patients not receiving a PVB did not differ significantly from that mentioned above (p = 0.40) ( Table 1 ). Axillary lymph node dissection was performed in 15 (39 %) patients in the PVB group and 13 (33 %) patients in the non-PVB group (p = 0.11). There was no significant difference regarding the timing of reconstruction after mastectomy (82 % delayed in PVB group vs. 74 % in non-PVB group, p = 0.41). There was no significant difference in median operative times between the two groups (483 min in PVB group vs. 506 min in non-PVB group, p [ 0.1).
Clinical Outcomes and Resource Utilization
Patients treated with a PVB versus standard anesthesia alone had significantly reduced median postoperative pain scores at 2 h (3 vs. 5, p \ 0.01) and 24 h (3 vs. 4, p \ 0.01) (Fig. 1) . Patients receiving a PVB exhibited significantly shorter median TTON compared to patients who did not receive a PVB (66 vs. 76 h, p \ 0.01) (Fig. 2) . Median hospital LOS for the PVB group was 95 h (interquartile range 89-114), significantly shorter than the median hospital LOS of 116 h (interquartile range 95-121) for the non-PVB group (p \ 0.01). This significance remained when analyzing the difference in LOS in hospital nights, with patients in the PVB group staying a median of four nights compared to a median of five nights for patients in the non-PVB group (p = 0.05) (Fig. 3) . Outcomes of interest for the study groups are presented in Table 2 . On evaluation of secondary outcomes, there was no significant difference between groups regarding the proportion of patients who developed postoperative nausea/vomiting (p = 0.26). There were no complications related to block administration. However, one patient had an inadequate anesthetic response to the PVB; this patient was not excluded from analysis.
DISCUSSION
To our knowledge, this is the first study to evaluate PVB in patients with breast cancer undergoing autologous microvascular breast reconstruction after mastectomy. This study demonstrates that preoperative PVB administration significantly reduces acute postoperative pain and hospital LOS for patients undergoing postmastectomy autologous breast reconstruction. Patients receiving a PVB experienced significantly improved pain control at 2 and 24 h postoperatively and were less dependent on intravenous opioids compared to patients who did not receive a PVB. Furthermore, hospital LOS was significantly reduced in both hours and days for patients receiving a PVB compared to patients who did not receive a PVB.
The findings from this study corroborate the existing literature that demonstrates PVB improves postoperative pain control in patients with breast cancer undergoing surgical treatment. 10, 11, 13 However, whereas all previous published studies regarding the role of PVB in breast reconstruction have only included patients undergoing prosthetic (implant/expander) reconstruction, this study expands our current understanding of the benefits of PVB to patients undergoing autologous breast reconstruction. This is an important distinction, as there is an evolving body of literature that demonstrates autologous tissue reconstruction, compared to prosthetic (tissue expander/ implant) reconstruction, is a cost-effective strategy in the long term and is associated with improved patient-reported quality of life and satisfaction with cosmetic outcomes for patients pursuing postmastectomy breast reconstruction. 6, 14 Furthermore, in patients requiring radiotherapy in addition to mastectomy for breast cancer treatment, autologous reconstruction is associated with higher patient satisfaction and lower complication rates compared to prosthetic reconstruction. 15 However, despite its many advantages, one of the major challenges with autologous reconstruction is that it is a more invasive procedure compared to prosthetic reconstruction and therefore is associated with increased acute postoperative pain. [16] [17] [18] Increased acute postoperative pain is a significant predictor of persistent postsurgical pain, which negatively affects quality of life and affects nearly 50 % of patients with breast cancer. [19] [20] [21] Furthermore, acute postoperative pain is associated with increased narcotic requirements and prolonged hospitalizations, contributing to additional resource utilization. 17, 18 Autologous microvascular breast reconstruction requires extensive dissection of the flap recipient site (chest wall) and usually involves rib resection for access to recipient vessels for flap anastomosis. Hospital LOSs are reported to be as high as 7-10 days after autologous reconstruction, contributing significantly to resource utilization. 17, 18, 22 For large-volume hospitals functioning at maximum capacity with operative waiting lists, prolonged hospitalizations represent lost financial revenue and potential treatment delays as they limit the ability to perform additional operations requiring inpatient hospitalization. Compounding this is the initiation of pay-for-performance programs and bundled care packages, where length of postoperative hospital stay is an increasingly emphasized quality metric that may affect financial reimbursement and provider reputation.
Therefore, improving acute postoperative pain control and recovery has significant implications for patients by enhancing physical, psychological, and social well-being and hospitals by improving resource utilization. This study demonstrates the ability of a PVB to improve the quality of care and enhance recovery for patients undergoing autologous breast reconstruction, resulting in superior patientreported pain outcomes and improved resource utilization with shorter hospitalizations. Prior studies by Coopey et al. and Fahy et al. separately demonstrated decreased LOS for patients receiving a PVB before prosthetic breast reconstruction. 10, 12 However, a limitation of these studies is that hospital LOS was only reported in hours. While this is valuable, a majority of hospital costs outside the operating room are related to overnight hospitalizations-that is, nights, not hours, spent in the hospital. We demonstrated that PVB administration also reduces LOS in hospital nights for patients undergoing autologous reconstruction, which could represent substantial cost savings for the health care system. This study does have a few limitations. Patients were not randomized to the exposure group in this cohort study. A potential selection and provider bias may exist in that anesthesiologists who were early adopters of the technique more aggressively advocated for a PVB compared to delayed adopters. Thus, if the potential benefits of a PVB were more clearly delineated to certain patients, these patients may have been more likely to opt for the intervention. A series of univariate comparisons was done between groups along known confounders, and the groups were found to be similar with respect to each of these, reducing the likelihood these variables confound the results; however, the potential for unknown confounding still exists. Further limitations are that we did not collect data on intraoperative narcotic administration and did not perform a long-term evaluation of pain, as we did not have adequate long-term follow-up on all patients to conduct this analysis; when 1-and 2-year follow-up data are available on all patients, this analysis will be performed in a supplementary study.
In conclusion, PVB administration was associated with significant improvements in postoperative pain control, shorter TTON, and reduced hospital LOS for patients undergoing autologous breast reconstruction after mastectomy. Further studies are needed to evaluate if increased adoption of this regional anesthesia technique has an impact on long-term health-related quality of life and will result in cost savings across the health care system. 
